ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gout"

  • Abstract Number: 1108 • ACR Convergence 2023

    Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout

    Brian LaMoreaux1, Chelsea McKibbon2, Katie Obermeyer1, Lissa Padnick-Silver1, Gerald Smith2, Jiaxuan Wang2 and Haridarshan Patel1, 1Horizon Therapeutics, Deerfield, IL, 2Cytel Inc., Vancouver, BC, Canada

    Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…
  • Abstract Number: 1888 • ACR Convergence 2023

    Solving the Final Puzzle of Gout Detection in DECT via Machine Learning-Based Mitigation of Pseudolesion-Related Challenges: Enhancing Diagnostic Accuracy

    Wan-Hee Yoo1, Eun Hae Park1, Dae-Woo Lee1, Riel Casto-Zunti2 and Yunjung Choi1, 1Jeonbuk National University Medical School, Jeonju, South Korea, 2University of Saskatchewan, Saskatoon, SK, Canada

    Background/Purpose: In a recent study, the low specificity of Dual-Energy CT (DECT) has raised concerns due to the frequent occurrence of pseudo lesions, also referred…
  • Abstract Number: 0237 • ACR Convergence 2023

    Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database

    Lissa Padnick-Silver1, Andrew Concoff2, Hong-Ye Gao1, Qianhong Fu1, Brian LaMoreaux1 and N. Lawrence Edwards3, 1Horizon Therapeutics, Deerfield, IL, 2United Rheumatology, Happauge, NY, 3University of Florida College of Medicine, Gainesville, FL

    Background/Purpose: Pegloticase, a recombinant pegylated uricase, rapidly reduces serum urate (SU) in patients refractory to/intolerant of oral urate-lowering therapies (ULTs).1,2 However, pegloticase is generally used…
  • Abstract Number: 0753 • ACR Convergence 2023

    Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System

    Jeremy Sullivan1, Anna Ware2, Gary Tarasovsky3, Cherish Wilson4, Mary Whooley3, Jasvinder Singh5, Jinoos Yazdany6 and Gabriela Schmajuk4, 1University of California San Francisco, San Francisco, CA, 2Palo Alto VA, Minneapolis, MN, 3San Francisco VA, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA, 5University of Alabama at Birmingham, Birmingham, AL, 6University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA

    Background/Purpose: New guidelines published in 2020 conditionally recommend HLA-B*58:01 allele testing for South Asian and Black patients receiving allopurinol to reduce the risk of severe…
  • Abstract Number: 1109 • ACR Convergence 2023

    Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis

    Blanka Stiburkova1, Katerina Pavelcova2, Jana Masinova1, Marketa Pavlikova3 and Karel Pavelka4, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology, Praha 2, Czech Republic, 3Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, 4Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic

    Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…
  • Abstract Number: 1909 • ACR Convergence 2023

    Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease

    Lena Eder1 and David Leverenz2, 1Duke University, Chapel Hill, NC, 2Duke University School of Medicine, Durham, NC

    Background/Purpose: Patients with gout and chronic kidney disease (CKD) are often not appropriately managed with goal-directed urate-lowering therapy (ULT). To address deficits in management of…
  • Abstract Number: 0238 • ACR Convergence 2023

    Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature

    Ellen Prendergast1, Nicola Dalbeth2, David Bursill3, Chris Frampton4 and Lisa Stamp4, 1Te Whatu Ora Southern, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3Royal Adelaide Hospital, Kensington Gardens, Australia, 4University of Otago, Christchurch, New Zealand

    Background/Purpose: Uniform terminology with standardised definitions for the various elements and states of a disease ensure accurate and consistent technical communication. In 2019 the Gout…
  • Abstract Number: 0811 • ACR Convergence 2023

    Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study

    Natalie McCormick1, Chio Yokose2, Jie Wei3, Na Lu4, Deborah Wexler1, Mary De Vera5, J. Antonio Avina-Zubieta4, Yuqing Zhang6 and Hyon K. Choi7, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Health Management Center, Xiangya Hospital Central South University, Changsha, China, 4Arthritis Research Canada, Vancouver, BC, Canada, 5University of British Columbia, Vancouver, BC, Canada, 6Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 7Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…
  • Abstract Number: 1110 • ACR Convergence 2023

    Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout

    Roy Fleischmann1, James Cheng-Chung Wei2, Zancong Shen3, sarah Morris4, Elizabeth Polvent5, Andrea Clouser-Roche4, Vijay Hingorani6, Rongzi Yan7, Shunqi Yan8, Robert Keenan9 and Li-Tain Yeh10, 1Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, 2Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, 3Arthrosi Therapeutics, San Diego, CA, 4Arthrosi Therapeutics Inc, San Diego, CA, 5Arthrosi Therapeutics, Inc., Roseville, CA, 6Vanguard Healthsciences, Inc., San Diego, CA, 7Arthrosi Therapeutics, Inc, Irvine, CA, 8Arthrosi Therapeutics, Inc., Laguna Hills, CA, 9Arthrosi Therapeutics, Chapel Hill, NC, 10Arthrosi Therapeutics, Inc., Irvine, CA

    Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…
  • Abstract Number: 2428 • ACR Convergence 2023

    Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors

    Natalie McCormick1, Kehuan Lin2, Chio Yokose3, Na Lu4, Yuqing Zhang1 and Hyon K. Choi5, 1Massachusetts General Hospital, Boston, MA, 2Channing Division of Network Medicine, Boston, MA, 3Massachusetts General Hospital, Waltham, MA, 4Arthritis Research Canada, Vancouver, BC, Canada, 5Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: A recent UK study reported a transient increased cardiovascular risk after gout flare episodes [Cipolletta et al. JAMA 2022], which may translate to premature…
  • Abstract Number: 0222 • ACR Convergence 2022

    Primary Care Provider Utilization of Musculoskeletal Ultrasound for the Diagnosis of Acute Gout Flares: A Novel Opportunity for Rheumatology-Focused Educational Curricula

    Wes Cubberley1, Taylor Nelson1, Michael Battistone2, Andrea Barker2, Jeremy Timm3, Anthony Minjarez2 and Gary Kunkel1, 1University of Utah, Salt Lake City, UT, 2Salt Lake City VA, Salt Lake City, UT, 3Salt Lake City VA, Salt Lake City

    Background/Purpose: Gout, the most common inflammatory arthritis, can be challenging to identify, especially when clinical criteria are insufficient to support a diagnosis. Musculoskeletal ultrasound (MSK…
  • Abstract Number: 1787 • ACR Convergence 2022

    The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study

    Puja Khanna1 and Ryan Beal2, 1University of Michigan, Ann Arbor, MI, 2Dyve Biosciences, Inc, Camarillo, CA

    Background/Purpose: Inflammatory cytokine-mediated bone resorption increases serum calcium (Ca2+) and can lead to calcification at chronically inflamed sites. Ca2+ influences cytokine activity to intensify the…
  • Abstract Number: 1806 • ACR Convergence 2022

    Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing

    Naomi Schlesinger1, Lissa Padnick-Silver2, Katie Obermeyer2 and Brian LaMoreaux2, 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Horizon Therapeutics plc, Deerfield, IL

    Background/Purpose: Acute gout flare often accompanies urate-lowering therapy initiation and is the most common adverse event associated with pegloticase, a recombinant pegylated uricase that rapidly…
  • Abstract Number: 1826 • ACR Convergence 2022

    Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis

    Sandra Hermann1, Andriko Palmowski1, Bukrhard Muche2, Kay-Geert Hermann3, Edgar Wiebe1 and Frank Buttgereit4, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Charité University Hospital, CCM, Berlin, Germany, 3Charité - Universitätsmedizin Berlin, Berlin, Germany, 4Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

    Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…
  • Abstract Number: 0550 • ACR Convergence 2022

    Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research

    Kazuki Yoshida, Tianrun Cai, Lily G Bessette, Erin Kim, Su Been Lee, Luke E Zabotka, Alec Sun, Julianna M. Mastrorilli, Theresa A. Oduol, Jun Liu, Daniel Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 45
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology